Top 5 Multiple Sclerosis Content of 2023

The top 5 most-read multiple sclerosis (MS) articles and interviews on AJMC.com this year included news on the progress of treatment options in MS, expert insights into the new mechanisms at work in novel treatments, and biomarker discoveries to better anticipate patient outcomes.

Here are the top-5 MS pieces of 2023.

5. Cognitive Benefits in Multiple Sclerosis Seen After Transcranial Current Stimulation

One of the core symptoms of MS is cognitive impairment. To broaden the scope of treatment for these effects, this study evaluated frontal theta-transcranial alternating current stimulation and found that a single session could improve cognitive function in patients with MS. This article was originally published by NeurologyLive^®.

Read the full article.

4. Internet-Based CBT Effective for Treating MS-Related Depression, Study Finds

Depression is a very common symptom that arises in patients who are enduring inflammatory or neurological disorders. In a phase 3 trial, researchers observed the impact of stand-alone and therapist-guided therapy done remotely and found that internet-based cognitive behavioral therapy (CBT) was an effective method for combatting depressive symptoms for patients with MS.

Read the full article.

3. Dr Erik Wallstroem and Tom Snow Highlight New MS Treatments Aimed at Smoldering Inflammation

In this interview, Erik Wallstroem, MD, PhD, global head of development, neurology and ophthalmology, and Tom Snow, global franchise head, neurology and rare blood disorders, both at Sanofi, discussed the recent development and approval of 3 novel treatments in MS: tolebrutinab, frexalimab, and SAR443820 (RIPK1i). The designs of these therapies aim to infiltrate the central nervous system and affect smoldering inflammation at its source.

Watch the full video.

2. Oral N-Acetylglucosamine Treatment Benefits Management of MS, Study Finds

Directly addressing the inflammation present in patients with MS is not enough to stimulate necessary myelin repair. N-acetylglucosamine has emerged as a promising supplement in MS treatment. This study demonstrated its efficacy in tackling and improving patients’ abilities to manage inflammation and immune responses stemming from their MS.

Read the full article.

1. Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening

In this study, neurofilament light changes exhibited promise as a biomarker of progression in MS. Researchers found that elevations in neurofilament light levels were linked to patterns of disability worsening in patients with MS. These changes were predictive of disease worsening approximately 1 year in advance. This article was originally published by NeurologyLive.

Read the full article.